A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

Trial status:Will Be Recruiting
Trial ID:
BNT323-01
NCT ID:
NCT06340568
EudraCT ID:
N/A
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
BioNTech SE
Will Be Recruiting

Trial Details

The goal of this clinical study is to assess the efficacy of BNT323/DB-1303 compared with investigator's choice of chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the endometrial cancer population.

Medical Condition
  • Endometrial Cancer
    • Trial Drug
  • BNT323/DB-1303
    • See more
  • Doxorubicin
  • Paclitaxel
    • Phase
    Phase 3
    Type
    Interventional
    Estimated Enrolment
    468
    Estimated Trial Date
    Jun 2025 - Oct 2027

    Trial Participant Requirements

    Age
    18+ years
    Sex
    Female
    Healthy Volunteers
    No

    Trial Locations

    No locations found.